CN116195744A - 用于干预焦虑引起的睡眠障碍的营养配方 - Google Patents
用于干预焦虑引起的睡眠障碍的营养配方 Download PDFInfo
- Publication number
- CN116195744A CN116195744A CN202310276101.0A CN202310276101A CN116195744A CN 116195744 A CN116195744 A CN 116195744A CN 202310276101 A CN202310276101 A CN 202310276101A CN 116195744 A CN116195744 A CN 116195744A
- Authority
- CN
- China
- Prior art keywords
- parts
- oil
- passion fruit
- anxiety
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000019901 Anxiety disease Diseases 0.000 title claims abstract description 49
- 230000036506 anxiety Effects 0.000 title claims abstract description 46
- 235000016709 nutrition Nutrition 0.000 title claims abstract description 46
- 208000019116 sleep disease Diseases 0.000 title claims abstract description 30
- 239000000203 mixture Substances 0.000 title claims abstract description 16
- 238000009472 formulation Methods 0.000 title claims abstract description 14
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims abstract description 48
- 239000000843 powder Substances 0.000 claims abstract description 42
- 244000288157 Passiflora edulis Species 0.000 claims abstract description 37
- 235000000370 Passiflora edulis Nutrition 0.000 claims abstract description 37
- 240000002900 Arthrospira platensis Species 0.000 claims abstract description 27
- 235000016425 Arthrospira platensis Nutrition 0.000 claims abstract description 27
- 229940082787 spirulina Drugs 0.000 claims abstract description 27
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims abstract description 26
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims abstract description 24
- 229930003944 flavone Natural products 0.000 claims abstract description 24
- 150000002212 flavone derivatives Chemical class 0.000 claims abstract description 24
- 235000011949 flavones Nutrition 0.000 claims abstract description 24
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims abstract description 24
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims abstract description 23
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims abstract description 21
- 239000003921 oil Substances 0.000 claims abstract description 21
- 235000019198 oils Nutrition 0.000 claims abstract description 21
- 241000219226 Acer truncatum Species 0.000 claims abstract description 20
- 235000015112 vegetable and seed oil Nutrition 0.000 claims abstract description 20
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 claims abstract description 18
- 108010038807 Oligopeptides Proteins 0.000 claims abstract description 18
- 102000015636 Oligopeptides Human genes 0.000 claims abstract description 18
- 235000010208 anthocyanin Nutrition 0.000 claims abstract description 18
- 229930002877 anthocyanin Natural products 0.000 claims abstract description 18
- 239000004410 anthocyanin Substances 0.000 claims abstract description 18
- 150000004636 anthocyanins Chemical class 0.000 claims abstract description 18
- 235000008191 folinic acid Nutrition 0.000 claims abstract description 18
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims abstract description 18
- 239000011672 folinic acid Substances 0.000 claims abstract description 18
- 229940106134 krill oil Drugs 0.000 claims abstract description 18
- 229960001691 leucovorin Drugs 0.000 claims abstract description 18
- 235000007516 Chrysanthemum Nutrition 0.000 claims abstract description 17
- 244000189548 Chrysanthemum x morifolium Species 0.000 claims abstract description 17
- 240000004307 Citrus medica Species 0.000 claims abstract description 17
- 240000000249 Morus alba Species 0.000 claims abstract description 17
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 17
- 240000000851 Vaccinium corymbosum Species 0.000 claims abstract description 17
- 235000003095 Vaccinium corymbosum Nutrition 0.000 claims abstract description 17
- 235000017537 Vaccinium myrtillus Nutrition 0.000 claims abstract description 17
- 235000021014 blueberries Nutrition 0.000 claims abstract description 17
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 17
- 244000223760 Cinnamomum zeylanicum Species 0.000 claims abstract description 16
- 235000017803 cinnamon Nutrition 0.000 claims abstract description 16
- 239000000341 volatile oil Substances 0.000 claims abstract description 16
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims abstract description 14
- 229940107187 fructooligosaccharide Drugs 0.000 claims abstract description 14
- 244000241838 Lycium barbarum Species 0.000 claims abstract description 12
- 235000015459 Lycium barbarum Nutrition 0.000 claims abstract description 12
- 235000004554 glutamine Nutrition 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 7
- 241000169546 Lycium ruthenicum Species 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 238000004140 cleaning Methods 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 239000006187 pill Substances 0.000 claims description 3
- 238000002791 soaking Methods 0.000 claims description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000006072 paste Substances 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 241001436793 Meru Species 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000007901 soft capsule Substances 0.000 claims 1
- 238000003860 storage Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 20
- 208000020685 sleep-wake disease Diseases 0.000 abstract description 20
- 230000035764 nutrition Effects 0.000 abstract description 18
- 230000007958 sleep Effects 0.000 abstract description 13
- 210000004556 brain Anatomy 0.000 abstract description 11
- 230000009471 action Effects 0.000 abstract description 7
- 239000000126 substance Substances 0.000 abstract description 7
- 210000005036 nerve Anatomy 0.000 abstract description 6
- 235000015097 nutrients Nutrition 0.000 abstract description 4
- 238000010521 absorption reaction Methods 0.000 abstract description 3
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 18
- 230000036039 immunity Effects 0.000 description 12
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 10
- 229940076279 serotonin Drugs 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 229940088597 hormone Drugs 0.000 description 7
- 239000005556 hormone Substances 0.000 description 7
- 206010022437 insomnia Diseases 0.000 description 7
- 229940088594 vitamin Drugs 0.000 description 7
- 235000013343 vitamin Nutrition 0.000 description 7
- 239000011782 vitamin Substances 0.000 description 7
- 229930003231 vitamin Natural products 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 206010062519 Poor quality sleep Diseases 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 229960003638 dopamine Drugs 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 4
- 230000000949 anxiolytic effect Effects 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000005284 excitation Effects 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 229910052749 magnesium Inorganic materials 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 239000011591 potassium Substances 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 230000002194 synthesizing effect Effects 0.000 description 4
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 3
- 206010013774 Dry eye Diseases 0.000 description 3
- 108010024636 Glutathione Proteins 0.000 description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
- 244000100205 Robinia Species 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- 239000002249 anxiolytic agent Substances 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 230000003925 brain function Effects 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 229960003180 glutathione Drugs 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- GWHCXVQVJPWHRF-KTKRTIGZSA-N (15Z)-tetracosenoic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCCCC(O)=O GWHCXVQVJPWHRF-KTKRTIGZSA-N 0.000 description 2
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 102000004882 Lipase Human genes 0.000 description 2
- 108090001060 Lipase Proteins 0.000 description 2
- 239000004367 Lipase Substances 0.000 description 2
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 2
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 2
- XJXROGWVRIJYMO-SJDLZYGOSA-N Nervonic acid Natural products O=C(O)[C@@H](/C=C/CCCCCCCC)CCCCCCCCCCCC XJXROGWVRIJYMO-SJDLZYGOSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- 210000004958 brain cell Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- GWHCXVQVJPWHRF-UHFFFAOYSA-N cis-tetracosenoic acid Natural products CCCCCCCCC=CCCCCCCCCCCCCCC(O)=O GWHCXVQVJPWHRF-UHFFFAOYSA-N 0.000 description 2
- 239000005515 coenzyme Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 2
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 2
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 235000019421 lipase Nutrition 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 229960003987 melatonin Drugs 0.000 description 2
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 2
- 230000004630 mental health Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000000944 nerve tissue Anatomy 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010002869 Anxiety symptoms Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 229910001369 Brass Inorganic materials 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010010947 Coordination abnormal Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 102000003638 Glucose-6-Phosphatase Human genes 0.000 description 1
- 108010086800 Glucose-6-Phosphatase Proteins 0.000 description 1
- 208000000857 Hepatic Insufficiency Diseases 0.000 description 1
- 102000005548 Hexokinase Human genes 0.000 description 1
- 108700040460 Hexokinases Proteins 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- 206010033664 Panic attack Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 208000013200 Stress disease Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000010951 brass Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 235000012716 cod liver oil Nutrition 0.000 description 1
- 239000003026 cod liver oil Substances 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 235000019788 craving Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000021196 dietary intervention Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 208000037870 generalized anxiety Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 208000016290 incoordination Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000005056 memory consolidation Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000001483 mobilizing effect Effects 0.000 description 1
- -1 mori fructus Natural products 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 208000024335 physical disease Diseases 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000012191 relaxation of muscle Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 230000037321 sleepiness Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/40—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds characterised by the fats used
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/30—Artificial sweetening agents
- A23L27/33—Artificial sweetening agents containing sugars or derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Microbiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明提供一种用于干预焦虑引起的睡眠障碍的营养配方,包括螺旋藻低聚肽粉、肉桂、百香果黄酮、磷虾油、菊花粉、黑枸杞花青素、桑葚、甲酰四氢叶酸、香橼精油、蓝莓、谷氨酰胺、元宝枫籽油、γ氨基丁酸、美藤果油、低聚果糖和香精。本发明以百香果黄酮、磷虾油、菊花粉、黑枸杞花青素、桑葚、甲酰四氢叶酸缓解焦虑功效,通过螺旋藻低聚肽粉提供营养组分,元宝枫籽油、γ氨基丁酸、蓝莓、美藤果油增加对脑部神经的作用以调节睡眠,调节整个营养配方的口感,实现营养物质平衡,促进对营养配方的吸收,达到调和阴阳治疗,从而实现干预焦虑引起的睡眠障碍。
Description
技术领域
本发明属于食品技术领域,具体涉及一种用于干预焦虑引起的睡眠障碍的营养配方。
背景技术
焦虑是一种常见的情绪,当其严重程度与客观事实不符,或持续时间过久,则成焦虑障碍又称焦虑症。包括广泛焦虑、惊恐发作、社交焦虑及应激障碍等。在日常生活中屡见不鲜,这些患者过分警觉,紧张不安,胆小害怕,敏感,或窒息感,胸部缩榨感,肌肉疼痛,失眠,尿频等。
睡眠作为生命所必须的过程,是中枢神经系统修复、生物节律维持、记忆巩固和机体整合的重要环节,是保持健康不可缺少的组成部分。失眠通常表现为入睡困难或睡眠质量差,是一种常见的生理、心理病患,给人们的正常工作和生活带来严重不良影响,甚至可能诱发或加重多种身体疾病。
针对焦虑引起的睡眠障碍,目前西医治疗主要使用苯二氮卓类药物、非苯二氮卓类药物、褪黑素类药物及抗抑郁药物等,西医治疗基本上都是从抑制中枢神经系统出发,达到促进睡眠的作用。虽然达到了睡眠效果,但次日醒来机体会出现困乏、疲倦的状态,且毒副作用大,长期使用此类药物也会产生一定的耐药性和成瘾性。
焦虑引起的睡眠障碍,又称为失眠症。焦虑引起的睡眠障碍会互相影响消化、免疫、代谢、激素及肝脏、大脑神经系统的正常功能,会出现睡困难、夜间多梦、夜间易醒、日间精力差、眼睛干涩、消化道不适、易早醒等,临床症状。焦虑引起的睡眠障碍属中医学“失眠”、“不寐”范畴,中医治疗失眠有其独到之处,多认为焦虑引起的睡眠障碍是由阴阳失衡引起,“胃不和则卧不安”、“思虑伤脾,脾血亏虚,经年不寐”、“人之安卧,神归心,魄归肺,魂归肝,意归脾,志归肾,五脏各安其位而寝”,并依据辩证论治原则将焦虑引起的睡眠障碍分为实证(如心火亢盛、肝郁气滞、痰热扰心、胃气不和等)、虚症(如心脾两虚、心胆气虚等)、虚实夹杂证(如阴虚火旺、心肾不交等),给予不同的方药,整体上调节机体生理,从根本上改善睡眠,服药期间不良反应少且不会出现成瘾性。
基于此,有必要提供一种用于干预焦虑引起的睡眠障碍的营养配方。
发明内容
本发明提供一种用于干预焦虑引起的睡眠障碍的营养配方,通过调节人体内营养物质均衡达到调和阴阳治疗,可以有效地减轻患者焦虑抑郁的临床症状,提高机体免疫力,改善了患者的营养状况,从而实现干预焦虑引起的睡眠障碍。
本发明通过以下技术方案进行实现:
一方面,本发明提供一种用于干预焦虑引起的睡眠障碍的营养配方,包括螺旋藻低聚肽粉、肉桂、百香果黄酮、磷虾油、菊花粉、黑枸杞花青素、桑葚、甲酰四氢叶酸、香橼精油、蓝莓、谷氨酰胺、元宝枫籽油、γ氨基丁酸、美藤果油、低聚果糖和香精。
进一步地,所述营养配方,包括螺旋藻低聚肽粉15-25份、肉桂15-25份、百香果黄酮15-25份、磷虾油15-25份、菊花粉15-25份、黑枸杞花青素15-25份、桑葚15-25份、甲酰四氢叶酸1-5份、香橼精油0.1-1份、蓝莓0.1-1份1-5份、谷氨酰胺0.1-0.5份、元宝枫籽油15-25份、γ氨基丁酸0.1-0.5份、美藤果油1-5份、低聚果糖0.0001-0.001份和香精0.0001-0.001份。
进一步地,所述营养配方,包括螺旋藻低聚肽粉20份、肉桂15份、百香果黄酮20份、磷虾油15份、菊花粉18份、黑枸杞花青素16份、桑葚20份、甲酰四氢叶酸1份、香橼精油0.5份、蓝莓0.6份3份、谷氨酰胺0.15份、元宝枫籽油15份、γ氨基丁酸0.25份、美藤果油3份、低聚果糖0.005份和香精0.001份。
进一步地,所述香橼精油的体积浓度为0.1%-50%。
进一步地,所述百香果黄酮的制备过程如下:将百香果清洗、粉碎、超声破壁、温水浸泡、离心、过滤、浓缩滤液处理得到。
进一步地,所述百香果黄酮的制备过程如下:将百香果清洗,电机功率800W粉碎1~5min,超声破壁,45℃温水与百香果按质量比10:1浸泡10min,离心,过滤、浓缩滤液处理得到。
值得注意的是,本发明所公开的各组分都是通过科学的依据(从抗焦虑相关的方剂)中筛选而得,通过将各组分有机结合,根据中医理论配伍,结合西医营养补充得到。
螺旋藻低聚肽粉富含氨基酸和维生素矿物质,富含的氨基酸是合成血清素、多巴胺的重要原料,血清素、多巴胺的平衡与焦虑、睡眠障碍密切相关;富含的维生素矿物质例如镁、钙、钾、铁等微量元素,能同时参与肌肉的收缩与放松、神经系统的传递、能够平衡血糖、降低血脂、增加血氧降低血压,降低抑制兴奋。螺旋藻中的钾、镁、锌、硒、VB、VC等是辅助合成血清素、多巴胺、SOD酶、谷胱甘肽及其他辅酶的重要原料。螺旋藻高钾、VB、镁、铁、氨基酸等成分与美藤果油或粉末组合共同作用于血糖、血压、调整睡眠。其中美藤果粉中也含有大量的氨基酸和微量元素也能够起到协同作用。
肉桂有温中补肾、散寒止痛功能,治腰膝冷痛,虚寒胃痛,慢性消化不良,腹痛吐泻,受寒经闭。《神农本草经》:“味辛温,主百病,养精神,和颜色,利关节,补中益气。为诸药先聘通使,久服通神,轻身不老。面生光华,眉好常如童子。”
百香果黄酮对神经具有保护作用,对多巴胺神经元有保护作用;百香果黄铜、γ氨基丁酸,都具有抗焦虑、抑郁、抑制兴奋的功效;
磷虾油的磷脂含有天然的二十碳五烯酸(EPA)和二十二碳六烯酸(DHA),这是一种抗炎脂肪酸,可以保持细胞膜健康平衡,抵御毒性、氧化和炎症攻击,提高人体免疫力的功效;
菊花粉富含19种氨基酸和多种微量元素,具有显著的清热祛火,提高免疫力的效果;
黑枸杞花青素具有较好的调节免疫、抗疲劳、降血压的作用;
桑葚富含蛋白质、人体必需的氨基酸、总糖、游离酸、粗纤维、维生素、矿物质等多种功能成分,具有较高的营养价值。其含有的维生素有VA、VC、VB、VE及胡萝卜素等,富有降血糖功效;
甲酰四氢叶酸具有显著的抗焦虑功效;
香橼用于提神醒脑、抗疲劳、焦虑,特别是香橼精油对焦虑症具有确切的疗效;
蓝莓防止脑神经老化,强心,抗癌,软化血管,增强人机体免疫;
谷氨酰胺可以改善精神障碍、癫痫病人脑功能;谷氨酰胺是降低皮质醇的作用,更多是谷氨酰胺与其他物质的组合作用;
美藤果油和谷氨酰胺从不同的靶点有改善脑功能的作用,其中美藤果中的ω-3还可以影响胆固醇,降低血脂,能抑制血小板聚集改善血液循,改善心脏功能,抑制兴奋;美藤果中的α-亚麻酸和谷氨酰胺两者结合针对不同的靶点,从不同方向协同起到改善脑功能,进而改善睡眠调整激素;美藤果粉中含有较多的色氨酸、螺旋藻中含有相对较少色氨酸,再有螺旋藻中维生素、镁钾锌硒、单独添加的VC等,这些微量元素和维生素是合成脱羧酶和羟化酶重要的营养物质。色氨酸在酶的作用下合成血清素,血清素是一种快乐激素,是改善焦虑的重要激素,同时血清素也是褪黑素的前体,使用螺旋藻和美藤果粉末是作为人体内合成血清素的原料。
元宝枫籽油富含神经酸,神经酸是大脑神经细胞和神经组织的核心天然成分,是迄今为止世界上发现的能促进受损神经组织修复和再生的特效物质,是神经细胞特别是大脑细胞、视神经细胞、周围神经细胞生长、再发育和维持的必须“高级营养素”。
γ氨基丁酸:(1)缓解焦虑和抑制兴奋:GABA在中枢神经系统中作为一种主要的抑制性神经递质起作用,参与脑循环生理活动。适当补充GABA,可缓解焦虑、抑制兴奋,从而起到改善睡眠的作用。(2)促进代谢:GABA可以在三羧酸循环(TCA)中提高己糖激酶的活性,进而加速脑中葡萄糖的代谢,终提高脑供血量与供氧量,促进睡眠。(3)提高记忆力:GABA通过舒缓压力,抑制神经元过度兴奋,提升中枢神经系统稳定性,增强大脑记忆区域的功能。(4)延缓神经细胞衰老:GABA可以提高葡萄糖磷酸酯酶的活性,参与大脑内三羧酸循环,活化脑细胞功能。
低聚果糖和香精调整整个营养配方的口感,使得口感清香。
焦虑人群,体内谷氨酸含量较高,螺旋藻、美藤果、谷氨酰胺,微量元素、维生素及氨基酸在脱羧酶、羟化酶和其他辅酶的作用下,更多的代谢谷氨酸,合成血清素、SOD酶、谷胱甘肽、多巴胺、γ氨基丁酸,是本发明保护方案中各组分用于干预焦虑引起的睡眠障碍的法宝。其中血清素是一种快乐激素,在较安全感的环境中产生,焦虑情况下更需要这种激素,而不是单一为了改善睡眠。本发明中添加百香果提取物主要是百香果中的黄酮物质能够抗焦虑、抗成瘾性、提高SOD酶的活性,由于在提取过程中会大量的损失VC,但是血清素、谷胱甘肽、SOD、γ氨基丁酸的合成都需要VC的参与,所以对于百香果提取物的制备更为小心,以求达到更好的效果。
螺旋藻和谷氨酰胺在不同的靶点影响人体免疫,同时又能协调共同作用于免疫,螺旋藻中的氨基酸和微量元素需要身体调动各种酶系统来代谢,调动酶系统过程中会提高人体的免疫机能,谷氨酰胺则从不同的靶点影响人体免疫从而可以协同作用。同时在调整消化道上也能通过不同靶点协同作用如对胃粘膜的修复和平衡胆汁调整肝脏功能。
另一方面,本发明提供一种用于干预焦虑引起的睡眠障碍的营养配方的制备方法,包括以下步骤:
将螺旋藻低聚肽粉、肉桂、百香果黄酮、磷虾油、菊花粉、黑枸杞花青素、桑葚、甲酰四氢叶酸、香橼精油、蓝莓、谷氨酰胺、元宝枫籽油、γ氨基丁酸、美藤果油、低聚果糖和香精混合均一,在前一组分添加混合均一后再添加后一组分,检测符合标准后,包装入库
进一步地,所述营养配方添加辅料制得片剂、粉剂、液剂、膏剂或蜜丸。
相对于现有技术,本发明提供的技术方案具备有益效果如下:
由于睡眠障碍会互相影响消化、免疫、代谢、激素及肝脏、大脑神经系统的正常功能,所以想要改善睡眠及其相关不适症状如眼睛干涩、消化不良、炎症因子高等,就必须对消化、免疫、代谢、激素及肝脏、大脑神经相关联的干预物质进行补充和平衡。
本发明中,以肉桂、百香果黄酮、磷虾油、菊花粉、黑枸杞花青素、桑葚、甲酰四氢叶酸缓解焦虑功效,通过螺旋藻低聚肽粉提供营养组分,元宝枫籽油、γ氨基丁酸、蓝莓、美藤果油增加对脑部神经的作用以调节睡眠,调节整个营养配方的口感,实现营养物质平衡,促进对营养配方的吸收,达到调和阴阳治疗,从而实现干预焦虑引起的睡眠障碍。
现有的抗焦虑营养配方仅关注配方的功效,忽略患者对于营养配方的体验感及长期的坚持性;本申请提供的抗焦虑引起的睡眠障碍的营养配方,从人性出发,更多考虑对营养配方的长期服用,减小患者的内心抗拒,可有效缓解人们的焦虑,有益身心健康。
本发明采取提供营养组分提升机体的抗免疫效果,提供药物组分缓解焦虑症状,配合对脑部神经的作用调节睡眠,本发明各组分协同作用,具有较好的协同促效作用,在满足人们的口感需求同时,从多方面对配方进行调整,最终将各组分相辅相成,共同作用,用于干预焦虑引起的睡眠障碍。
本发明提供的营养配方无毒副作用、易吸收,用于治疗焦虑引起的失眠症,并且本发明可作为膳食补充剂或保健食品原料,用于预防或者治疗焦虑症、促进心理健康。
本发明的营养配方对入睡困难、夜间多梦、夜间易醒、日间精力、眼睛干涩、消化道不适、易早醒等,临床症状有很好的改善效果。
此外,将元宝枫子油、美藤果油与脂肪酶混合酶解,再混合其它组分做成凝胶糖果后,可直接到达肠道减少胃酸胆盐的破坏增加有效吸收。凝胶糖果即鱼肝油透明胶囊类的剂型。
具体实施方式
为了让本领域技术人员更加清楚明白本发明所述技术方案,现列举以下实施例进行说明。需要指出的是,以下实施例对本发明要求的保护范围不构成限制作用。以下实施例旨在说明本发明内容,而不是对本发明保护范围的进一步限定。
百香果黄酮的制备过程如下:将百香果清洗,电机功率800W粉碎3min,超声破壁,45℃温水与百香果按质量比10:1浸泡10min,离心,过滤、浓缩滤液处理得到。
实施例1:
一种用于干预焦虑引起的睡眠障碍的营养配方,包括螺旋藻低聚肽粉20份、肉桂15份、百香果黄酮20份、磷虾油15份、菊花粉18份、黑枸杞花青素16份、桑葚20份、甲酰四氢叶酸1份、香橼精油0.5份、蓝莓0.6份3份、谷氨酰胺0.15份、元宝枫籽油15份、γ氨基丁酸0.25份、美藤果油3份、低聚果糖0.005份和香精0.001份。
将螺旋藻低聚肽粉、肉桂、百香果黄酮、磷虾油、菊花粉、黑枸杞花青素、桑葚、甲酰四氢叶酸、香橼精油、蓝莓、谷氨酰胺、元宝枫籽油、γ氨基丁酸、美藤果油、低聚果糖和香精混合均一,在前一组分添加混合均一后再添加后一组分,检测符合标准后,包装入库。
实施例2:
一种用于干预焦虑引起的睡眠障碍的营养配方,包括螺旋藻低聚肽粉25份、肉桂25份、百香果黄酮15份、磷虾油25份、菊花粉15份、黑枸杞花青素25份、桑葚15份、甲酰四氢叶酸5份、香橼精油0.1份、蓝莓1份1份、谷氨酰胺0.5份、元宝枫籽油15份、γ氨基丁酸0.5份、美藤果油1份、低聚果糖0.001份和香精0.001份。
将螺旋藻低聚肽粉、肉桂、百香果黄酮、磷虾油、菊花粉、黑枸杞花青素、桑葚、甲酰四氢叶酸、香橼精油、蓝莓、谷氨酰胺、元宝枫籽油、γ氨基丁酸、美藤果油、低聚果糖和香精混合均一,在前一组分添加混合均一后再添加后一组分,检测符合标准后,包装入库。
实施例3:
一种用于干预焦虑引起的睡眠障碍的营养配方,包括螺旋藻低聚肽粉20份、肉桂16份、百香果黄酮20份、磷虾油20份、菊花粉20份、黑枸杞花青素20份、桑葚20份、甲酰四氢叶酸3份、香橼精油0.3份、蓝莓0.9份3份、谷氨酰胺0.3份、元宝枫籽油20份、γ氨基丁酸0.2份、美藤果油3份、低聚果糖0.0005份和香精0.0008份。
将螺旋藻低聚肽粉、肉桂、百香果黄酮、磷虾油、菊花粉、黑枸杞花青素、桑葚、甲酰四氢叶酸、香橼精油、蓝莓、谷氨酰胺、元宝枫籽油、γ氨基丁酸、美藤果油、低聚果糖和香精混合均一,在前一组分添加混合均一后再添加后一组分,检测符合标准后,包装入库。
实施例4小鼠高架十字迷宫实验(HPM)
高架十字迷宫装置为两条相对开放臂(50cm长×10cm宽)和两条相对闭合臂(50cm长×l0cm宽×40cm高)及中央区(10cm×l0cm)连接而成,将小鼠放于中央区,记录内小鼠进入开放臂的次数,在开放臂的停留时间以及在开放臂的运动距离。用Smart软件进行录像分析。每只小鼠测试完毕需要用酒精擦洗箱底。
实验结果以平均值±标准误差表示,以t检验统计处理。
高架十字迷宫是利用动物对新异环境的探究特性和对高悬敞开臂的恐惧形成矛盾冲突行为来考察动物的焦虑状态。有效的抗焦虑产品会增加小鼠在高架十字迷宫实验中小鼠进入开放臂的次数以及运动距离。
结果发现,本发明营养配方分散于水中灌胃与溶媒组对比,显著的增加了小鼠进入开放臂的次数以及运动距离。说明本发明营养配方灌胃可以增加高架十字迷宫实验中小鼠进入开放臂的次数以及运动距离。
实施例5
1.研究对象
研究对象均来自某医院临床门诊病例,并符合以下标准:1)年龄:20~50周岁;2)性别:男性或女性,女性受试者应为非妊娠和非哺乳期女性;3)受试者自愿签署经伦理委员会批准的知情同意书;4)具有入睡困难、夜间多梦、夜间易醒、日间精力差、眼睛干涉、易早醒等症状者入组。符合下列标准一条或多条的受试者将被排除:1)使用降糖药物(阿卡波糖、二甲双胍、格列本脲等)的糖尿病患者;2)既往接受胰岛素及胰岛素类似物治疗者,严重糖尿病慢性并发症者;3)患有严重消化、心血管、呼吸、泌尿系统或遗传代谢性疾病,肝肾功能不全(衰弱)以及先天性免疫缺陷病等任何临床严重疾病史者或恶性肿瘤病史者。
2.试验方法
采用开放、自身对照试验设计,试验周期为28天,整个试验期间总摄入产品剂量为500g。试验期间不用饮食控制,入组的受试者通过24小时膳食回顾法对患者的饮食习惯等进行营养评估,受试者在组期间,使用本产品替代晚餐的部分主食,餐前30~40分钟食用。设置两组,每组试验周期结束后进行测试询问。
3.结果
通过28天的饮食干预结果如下:
入睡困难、夜间多梦、夜间易醒、日间精力差、眼睛干涉、易早醒症状,在干预后的第2天得到有效改善,在实施干预后的28天完全消失。
4.结论
本发明采用结合饮食替代方法,在饮食调整过程中,保证了个体的营养均衡,焦虑引起的睡眠障碍有效得到改善,且几乎完全消失。研究表明本发明的营养配方能有效改善焦虑引起的睡眠障碍。
虽然,上文中已经用一般性说明、具体实施方式及试验,对本发明作了详尽的描述,但在本发明基础上,可以对之作一些修改或改进,这对本领域技术人员而言是显而易见的。因此,在不偏离本发明精神的基础上所做的这些修改或改进,均属于本发明要求保护的范围。
Claims (9)
1.一种用于干预焦虑引起的睡眠障碍的营养配方,其特征在于,包括螺旋藻低聚肽粉、肉桂、百香果黄酮、磷虾油、菊花粉、黑枸杞花青素、桑葚、甲酰四氢叶酸、香橼精油、蓝莓、谷氨酰胺、元宝枫籽油、γ氨基丁酸、美藤果油、低聚果糖和香精。
2.根据权利要求1所述的营养配方,其特征在于,包括螺旋藻低聚肽粉15-25份、肉桂15-25份、百香果黄酮15-25份、磷虾油15-25份、菊花粉15-25份、黑枸杞花青素15-25份、桑葚15-25份、甲酰四氢叶酸1-5份、香橼精油0.1-1份、蓝莓0.1-1份1-5份、谷氨酰胺0.1-0.5份、元宝枫籽油15-25份、γ氨基丁酸0.1-0.5份、美藤果油1-5份、低聚果糖0.0001-0.001份和香精0.0001-0.001份。
3.根据权利要求1所述的营养配方,其特征在于,包括螺旋藻低聚肽粉20份、肉桂15份、百香果黄酮20份、磷虾油15份、菊花粉18份、黑枸杞花青素16份、桑葚20份、甲酰四氢叶酸1份、香橼精油0.5份、蓝莓0.6份3份、谷氨酰胺0.15份、元宝枫籽油15份、γ氨基丁酸0.25份、美藤果油3份、低聚果糖0.005份和香精0.001份。
4.根据权利要求1所述的营养配方,其特征在于,所述百香果黄酮的制备过程如下:将百香果清洗、粉碎、超声破壁、温水浸泡、离心、过滤、浓缩滤液处理得到。
5.根据权利要求4所述的营养配方,其特征在于,所述百香果黄酮的制备过程如下:将百香果清洗,电机功率800W粉碎1~5min,超声破壁,45℃温水与百香果按质量比10:1浸泡10min,离心,过滤、浓缩滤液处理得到。
6.根据权利要求1所述的营养配方,其特征在于,所述营养配方与辅料制成任何一种常用的口服药剂。
7.根据权利要求6所述的营养配方,其特征在于,所述口服药剂为片剂、丸剂、软胶囊剂、粉剂、液剂、膏剂或蜜丸。
8.一种如权利要求1所述营养配方的制备方法,其特征在于,包括以下步骤:
将螺旋藻低聚肽粉、肉桂、百香果黄酮、磷虾油、菊花粉、黑枸杞花青素、桑葚、甲酰四氢叶酸、香橼精油、蓝莓、谷氨酰胺、元宝枫籽油、γ氨基丁酸、美藤果油、低聚果糖和香精,在前一组分添加混合均一后再添加后一组分,检测符合标准后,包装入库。
9.一种如权利要求1所述营养配方在制备治疗焦虑引起的睡眠障碍的药物中的用途。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310276101.0A CN116195744A (zh) | 2023-03-21 | 2023-03-21 | 用于干预焦虑引起的睡眠障碍的营养配方 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310276101.0A CN116195744A (zh) | 2023-03-21 | 2023-03-21 | 用于干预焦虑引起的睡眠障碍的营养配方 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116195744A true CN116195744A (zh) | 2023-06-02 |
Family
ID=86507773
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310276101.0A Pending CN116195744A (zh) | 2023-03-21 | 2023-03-21 | 用于干预焦虑引起的睡眠障碍的营养配方 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116195744A (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104856000A (zh) * | 2015-04-23 | 2015-08-26 | 劲膳美生物科技股份有限公司 | 失眠非全营养配方食品 |
CN110193074A (zh) * | 2019-07-03 | 2019-09-03 | 姚子昂 | 一种内服治疗神经衰弱症状的中药组合物及其制备方法 |
CN112205507A (zh) * | 2020-09-30 | 2021-01-12 | 米宝有约(北京)医疗科技有限公司 | 一种能改善睡眠的组合物、保健食品、药物制剂及其制备方法与应用 |
CN113040393A (zh) * | 2021-03-31 | 2021-06-29 | 杨继辉 | 一种干预焦虑睡眠障碍的营养配方 |
-
2023
- 2023-03-21 CN CN202310276101.0A patent/CN116195744A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104856000A (zh) * | 2015-04-23 | 2015-08-26 | 劲膳美生物科技股份有限公司 | 失眠非全营养配方食品 |
CN110193074A (zh) * | 2019-07-03 | 2019-09-03 | 姚子昂 | 一种内服治疗神经衰弱症状的中药组合物及其制备方法 |
CN112205507A (zh) * | 2020-09-30 | 2021-01-12 | 米宝有约(北京)医疗科技有限公司 | 一种能改善睡眠的组合物、保健食品、药物制剂及其制备方法与应用 |
CN113040393A (zh) * | 2021-03-31 | 2021-06-29 | 杨继辉 | 一种干预焦虑睡眠障碍的营养配方 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102224891B (zh) | 一种糖醇蜂蜜苹果酱及其制备方法 | |
CN1625406A (zh) | 用于预防和治疗温血动物的应激状态的含有溶血磷脂酰丝氨酸的制剂 | |
CN103859379A (zh) | 一种有助于改善记忆的养生保健食品配方及其制备方法 | |
CN106107463A (zh) | 超级藜麦抗疲劳奶茶制作工艺 | |
CN109820905A (zh) | 一种治疗失眠的药物组合物及其应用 | |
CN1939520A (zh) | 一种可改善记忆的益智胶囊及其制备工艺 | |
CN105232907A (zh) | 一种补肾壮阳饮料及其制备方法 | |
CN110934976A (zh) | 一种治疗近视的药物及其制备方法 | |
CN103461585A (zh) | 补气养生中药茶 | |
CN105249440A (zh) | 一种阿胶糕 | |
CN113040393A (zh) | 一种干预焦虑睡眠障碍的营养配方 | |
CN105011146B (zh) | 一种有助于改善睡眠的组合物及其制备方法和应用 | |
CN107028169A (zh) | 一种改善记忆力的组合物及其制备方法 | |
CN109673802A (zh) | 一种磷脂酰丝氨酸益智仁压片糖果及制备方法和应用 | |
CN116195744A (zh) | 用于干预焦虑引起的睡眠障碍的营养配方 | |
CN103829342A (zh) | 功能性保健饮料及其制备方法 | |
CN106800992A (zh) | 桑椹阿胶人参酒及其制备方法 | |
CN103656150B (zh) | 一种养生保健口服液及其制备方法 | |
CN106035686A (zh) | 超级藜麦养生植物奶 | |
CN102326655A (zh) | 绿色保健长寿果 | |
FR2916637A1 (fr) | Traitement naturel de desintoxication d'alcool, sevrage progressif, a l'abstinence totale a long terme. prevention des cancers du a ses mefaits, de l'hepatite c, cirrhose et cardiovasculaire, diabete | |
CN110651983A (zh) | 一种高蛋白营养粉及其制备方法 | |
CN108703373A (zh) | 一种七色营养素 | |
CN106213157A (zh) | 超级藜麦学生营养包制作工艺 | |
CN105169373A (zh) | 一种适宜儿童服用的营养口含片及制法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |